Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Dosimetry and Efficacy of BPR-6023021 in Subjects With Advanced Solid Tumors With Bone Metastases.

NCT07249892 is registered in ClinicalTrials.gov with Chengdu Syncor Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07249892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07249892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Dosimetry and Efficacy of BPR-6023021 in Subjects With Advanced Solid Tumors With Bone Metastases.
Lead sponsor
Chengdu Syncor Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 19, 2025
Completion date
September 6, 2027
Enrollment
195 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumors